Palisade Bio Inc (NASDAQ:PALI) shares are trading higher after the company announced a licensing agreement with Giiant Pharma Inc. The license provides Palisade with exclusive worldwide rights to develop, manufacture, and commercialize Giiant's proprietary targeted prodrug platform for the IBD market. The licensed technologies include Giiant's precision delivery technology platform and multiple product candidates. Palisade will pay a portion of the development costs until the first approval of an IND or CTA, after which it will assume all costs.